Trials / Completed
CompletedNCT03185793
Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia
Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia (Asymptomatic and Gout)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 198 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to assess efficacy and safety of SHR4640 in subjects with hyperuricemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo once daily for 5 weeks |
| DRUG | SHR4640 | 1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks |
| DRUG | benzbromarone | 25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks |
Timeline
- Start date
- 2017-07-20
- Primary completion
- 2018-07-20
- Completion
- 2018-07-20
- First posted
- 2017-06-14
- Last updated
- 2019-08-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03185793. Inclusion in this directory is not an endorsement.